United Therapeutics — Third Quarter 2026 Earnings Summary

United Therapeutics Corporation reported third-quarter 2026 total revenues of $832.5 million, representing a 4% increase from the same period in 2025. Net income for the quarter was $258.6 million, a 24% decline compared to $338.7 million in the prior year, driven by a significant increase in research and development expenses. Revenue growth was primarily fueled by a 13% rise in Tyvaso DPI sales and an 11% increase in Orenitram sales, which partially offset declines in Nebulized Tyvaso and Adcirca. The company also executed accelerated share repurchase agreements totaling approximately $1.98 billion during the quarter and announced a new $2.0 billion share repurchase authorization in October 2026.